Connect Biopharma Reports Q3 2025 Results and Advances Rademikibart Clinical Programs
Connect Biopharma Holdings Ltd. reported its Q3 2025 financial results, highlighting ongoing recruitment for Phase 2 Seabreeze STAT studies on rademikibart for asthma and COPD, with topline data expected in H1 2026. In China, Simcere submitted a New Drug Application for rademikibart for atopic dermatitis, accepted by the National Medical Products Administration. The company also terminated its American Depositary Receipt program and listed its shares on Nasdaq under "CNTB". As of September 30, 2025, it had $54.8 million in cash and equivalents, sufficient to fund operations into 2027.
Connect Biopharma Holdings Ltd. reported financial results for the third quarter of 2025 and provided a business update. The company announced ongoing recruitment for its Phase 2 Seabreeze STAT studies evaluating rademikibart in acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD), with topline data expected in the first half of 2026. In China, Simcere, Connect Biopharma’s exclusive licensee, submitted a New Drug Application for rademikibart for the treatment of atopic dermatitis, which was accepted by the National Medical Products Administration in July 2025. The company also presented positive data at ERS 2025 highlighting the potential of rademikibart in patients with a range of type 2 inflammatory markers. Connect Biopharma completed the termination of its American Depositary Receipt program and directly listed its ordinary shares on the Nasdaq Global Market under the symbol “CNTB”. As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $54.8 million. The company expects this to be sufficient to fund operations into 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001835268-25-000057), on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
